Telix Pharmaceuticals (ASX:TLX) announced on Monday it has filed early-stage paperwork proposing to US regulators a listing on the American equities markets.
Morgan Stanley and Jefferies are among the firms acting as managers for the IPO process, signifying a high level of confidence from Telix it intends to go forward with the plan.
A US prospectus is already lined up for exclusive US release; Telix is ultimately aiming for the NASDAQ.
Notably, the move comes as the ASX experiences uncharacteristically quiet newsflow volumes through 2024 in an environment where bonds and commodities have seduced many away from domestic equities.
Telix is seeking to offer American Depository Shares (ADSs) under the ticker it uses down under, TLX.
TLX closed on Friday at A$14.80/sh.